Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine

OBJECTIVE: Despite the high vaccine efficacy of mRNA COVID‐19 vaccines, there are individuals who developed excessive reactogenic and/or allergic responses after the first mRNA dose and were considered ineligible for further mRNA doses. CoronaVac, an inactivated SARS‐CoV‐2 vaccine, is recommended in...

Descripción completa

Detalles Bibliográficos
Autores principales: Goh, Yun Shan, Fong, Siew‐Wai, Rouers, Angeline, Chang, Zi Wei, Tay, Matthew Zirui, Chavatte, Jean‐Marc, Zhuo, Nicole Ziyi, Hor, Pei Xiang, Loh, Chiew Yee, Huang, Yuling, Wong, Joel Xu En, Tan, Yong Jie, Lim, Daniel Rui Xiang, Wang, Bei, Ngoh, Eve Zi Xian, Salleh, Siti Nazihah Mohd, Lee, Raphael Tze Chuen, Pada, Surinder, Sun, Louisa Jin, Ong, Desmond Luan Seng, Somani, Jyoti, Lee, Eng Sing, Maurer‐Stroh, Sebastian, Wang, Cheng‐I, Leo, Yee‐Sin, Lin, Raymond TP, Ren, Ee Chee, Lye, David C, Young, Barnaby Edward, Lim, Poh Lian, Ng, Lisa FP, Renia, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398778/
https://www.ncbi.nlm.nih.gov/pubmed/36016852
http://dx.doi.org/10.1002/cti2.1403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398778/
https://www.ncbi.nlm.nih.gov/pubmed/36016852
http://dx.doi.org/10.1002/cti2.1403

Ejemplares similares